From Translational and Clinical Research
Partnering primary investigators, Sofia Merajver, M.D., Ph.D., and Goutham Narla, M.D., Ph.D., received two inter-programmatic Department of Defense Breast Cancer Research Program Breakthrough Awards. The three year awards, totaling $2.3M, study the therapeutic reactivation of the PP2A tumor suppressor for breast cancer treatment.
$100K+ Grants Awarded in March
Joshi Alumkal, M.D.: P50 SubK [Overall PI: Peter Nelson (Fred Hutchinson Cancer Research Center)] ($132K) “Targeting Emerging Vulnerabilities in AR-Independent Prostate Cancer” (DT)
Howard Crawford, Ph.D.: R01 ($2.4M) "Metaplastic Tuft Cells in Pancreatic Cancer" (CB)
Meredith Morgan, Ph.D.: R01 ($2.3M) "Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer" (DT)
Costas Lyssiotis, Ph.D.: $200K SubK from Cornell University (Prime Sponsor: The Mark Foundation for Cancer Research) for “Malic enzyme dependence is a therapeutic vulnerability in pancreatic cancer” (CB)